Menu Search
Equities

Hofseth Biocare ASA

HBQ:DEU

Hofseth Biocare ASA

Actions
  • Price (EUR)0.11
  • Today's Change-0.003 / -2.65%
  • Shares traded0.00
  • 1 Year change-51.75%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in NOKIncome statement in NOKView more

Year on year Hofseth Biocare ASA grew revenues 61.79% from 120.45m to 194.87m while net income improved from a loss of 137.39m to a smaller loss of 106.68m.
Gross margin27.71%
Net profit margin-55.65%
Operating margin-49.03%
Return on assets-34.79%
Return on equity-134.48%
Return on investment-70.98%
More ▼

Cash flow in NOKView more

In 2023, cash reserves at Hofseth Biocare ASA fell by 8.54m. Cash Flow from Financing totalled 3.69m or 1.90% of revenues. In addition the company generated 2.76m in cash from operations while cash used for investing totalled 14.99m.
Cash flow per share-0.2332
Price/Cash flow per share--
Book value per share0.2524
Tangible book value per share0.1446
More ▼

Balance sheet in NOKView more

Hofseth Biocare ASA has a Debt to Total Capital ratio of 64.25%, a lower figure than the previous year's 92.76%.
Current ratio0.7265
Quick ratio0.3595
Total debt/total equity1.79
Total debt/total capital0.6425
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.